Best Brand-Name GLP-1 Telehealth Providers 2026

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

If you've been shopping for an online GLP-1 prescription, you've already noticed the market splits cleanly into two lanes. Lane one is the brand-name lane — Ro, Walgreens, GoodRx Care, Hims & Hers, PlushCare, Sesame, and WeightWatchers all dispense FDA-approved finished drugs like Wegovy (semaglutide), Zepbound (tirzepatide), and the new Foundayo daily oral GLP-1. Lane two is the compounded lane — cash-pay platforms that route through licensed U.S. compounding pharmacies and price below the branded list. This article maps the brand-name lane the way a buyer should read it — true month-one cost, what each provider actually dispenses, who handles insurance — and then explains exactly where PlexusDx Semaglutide Injection, Tirzepatide Injection, and the Microdose GLP-1 Protocol sit when branded coverage isn't accessible. Most commercial plans still don't cover GLP-1s for weight loss in 2026, which is why the compounded option matters even when the branded providers look attractive on a landing page.

Brand-name GLP-1 telehealth providers — the seven-platform field in April 2026

Seven providers anchor the brand-name lane. Ro charges $39 for the first month then $149/mo (or $74/mo on the annual plan) for the platform; medication is billed separately, with Wegovy pen at $199/mo, Zepbound vials at $299/mo, and Wegovy pill or Foundayo at $149/mo on starting doses. Walgreens Weight Management is no-subscription — $49 per visit, with the same Novo Nordisk introductory medication pricing. GoodRx Care runs a $39/mo membership with retail-pharmacy pickup. Hims & Hers mirrors Ro's $39-then-$149 structure but isn't available in all 50 states and doesn't position around an insurance concierge. PlushCare is the traditional doctor-and-insurance route at $19.99/mo plus visit fees. Sesame is a marketplace ($99/mo or $59/mo annual) with Costco-member discounts. WeightWatchers Med+ bundles coaching with a 12-month commitment. Every one of these dispenses FDA-approved finished GLP-1 medications — the same Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus, and Foundayo you'd get at retail pharmacy.

What 'FDA-approved' actually means here — and what it doesn't

FDA approval applies to the finished drug product, not the active ingredient in isolation. Wegovy and Ozempic are FDA-approved finished semaglutide products; Zepbound and Mounjaro are FDA-approved finished tirzepatide products; Saxenda (liraglutide), Rybelsus (oral semaglutide), Trulicity (dulaglutide), Victoza (liraglutide), and Foundayo (the new daily oral) round out the approved roster. Compounded semaglutide and compounded tirzepatide — the products PlexusDx and other cash-pay platforms dispense — are pharmacy-prepared formulations of the same active ingredients. They are not FDA-approved finished drugs and we never describe them that way. The distinction matters for two reasons: regulatory framework and supply consistency. It does not mean the active molecule is different. The boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies regardless of whether the product is branded or compounded.

The real month-one cost — brand-name vs PlexusDx compounded

Most brand-name comparisons quote a platform fee and stop there. The honest number is platform fee plus medication. On Ro's $39-first-month plan, true month-one for the Wegovy pill or Foundayo is $188 ($39 + $149); for the Wegovy pen it's $238 ($39 + $199); for Zepbound vials it's $338 ($39 + $299). Walgreens runs $198 for the oral entry and $248 for the injectable. GoodRx Care comes out to $188 oral and $238 injectable. Hims & Hers matches Ro's intro but jumps to $298–$348/mo ongoing once the promo expires. Without insurance covering the branded drug at a low copay, year-two annualized costs land between $2,256 and $4,176 on the lower-tier branded paths and well above $10,000 if Zepbound vials stay at $299/mo. PlexusDx Microdose GLP-1 Protocol is $129/mo flat — $1,548/year, all-inclusive of the consultation, the compounded medication, and shipping. Semaglutide Injection runs $149/mo ($2,148–$2,748/year), Tirzepatide Injection runs $249/mo ($2,748–$3,708/year), and GLP-Squared dual-compound is $249/mo. There is no platform fee layered on top — PlexusDx is no-membership, all-inclusive, all 50 states (five require a live consult).

Why most commercial plans still don't cover branded GLP-1s for weight loss

This is the structural reason cash-pay compounded GLP-1 exists. The branded GLP-1 medications approved for chronic weight management — Wegovy, Zepbound, Saxenda, and now Foundayo — sit on payer formularies as some of the most expensive new drugs of the decade. Many commercial insurance plans exclude weight-loss drugs categorically; many others require step therapy, BMI thresholds, comorbidity documentation, and prior-authorization paperwork before approving coverage; many Medicare Part D plans still cannot cover the same molecules for weight loss even when they cover them for diabetes (Ozempic, Mounjaro, Rybelsus). When the prior authorization is denied or the plan excludes the category outright, the patient is back to cash-pay branded prices — which is where Ro's $499/mo Lilly Direct option, Walgreens' $199/mo Novo Direct intro, and the compounded cash-pay route from PlexusDx become the actual choices on the table. None of those routes require insurance approval; PlexusDx in particular is structured cash-pay end-to-end, so the patient is not waiting on a payer decision before starting.

When the brand-name lane fits — and when PlexusDx is the better cash-pay path

The brand-name lane fits cleanly in three situations. First: your commercial plan covers Wegovy or Zepbound at a low copay — the FDA-approved branded product is then almost always cheaper than any cash-pay path. Second: you specifically want the FDA-approved finished drug and are willing to pay $499/mo (Lilly Direct Zepbound) or $199/mo (Novo Direct intro Wegovy pen) cash. Third: you want the new branded daily oral — Foundayo or Wegovy pill — available through Ro, GoodRx, or Walgreens at $149/mo medication. The compounded cash-pay path through PlexusDx fits when none of those apply. If your insurance excludes weight-loss drugs, if a prior authorization has been denied, if the branded list price is above your budget, or if you want a baseline genetic test informing the dose decision before titration begins — those are the cases where Semaglutide Injection at $149/mo or the entry-tier Microdose GLP-1 Protocol at $129/mo flat does the work the brand-name lane can't.

What PlexusDx adds that the brand-name lane doesn't

Three things separate the PlexusDx model from a generic compounded competitor as well as from the brand-name field. First, format flexibility — six prescription compounds across four mechanism classes, including weekly injection, daily oral tablet, microdose troche/capsule/lozenge/sublingual, and dual-compound semaglutide-plus-tirzepatide stacks. The brand-name lane gives you a pen or a pill in fixed-dose increments; PlexusDx gives a clinician a wider titration palette. Second, all-inclusive cash-pay with no membership and no platform fee — the monthly price is the monthly price. Third, an optional genetic baseline. The Precision Peptide Genetic Test ($298 standalone, or $99 as an add-on after your first month on any protocol) maps 48 genes and 57 variants across 14 health pathways — including 34 weight-management insights and the GIPR rs1800437 variant linked to differential GLP-1 response. Neither Ro nor Walgreens nor any of the other branded telehealth platforms includes genetic stratification — all begin with a population-average titration and adjust based on subjective tolerability.

How to choose between the seven brand-name providers and PlexusDx

Run a four-question filter. Question one: does your insurance reliably cover Wegovy or Zepbound at a low copay? If yes, Ro or PlushCare with insurance support is the cheapest answer. Question two: are you cash-pay with no GLP-1 coverage and want the FDA-approved branded drug specifically? Walgreens for the no-subscription model, Ro or GoodRx for the lowest oral entry, Hims & Hers for an app-first UX. Question three: are you cash-pay, the branded list price is out of reach, and total annual cost is the dominant factor? Compare PlexusDx Microdose GLP-1 Protocol at $1,548/year, Semaglutide Injection at $2,148–$2,748/year, and Tirzepatide Injection at $2,748–$3,708/year directly against the cash-pay branded annual numbers. Question four: do you want a genetic baseline informing dose and titration before week one? PlexusDx is the only option here that includes the Precision Peptide Genetic Test as part of the protocol pathway.

Frequently asked questions

What is the best brand-name GLP-1 telehealth provider in 2026?

For most cash-pay shoppers wanting the FDA-approved branded drug, Ro is the most-cited overall pick because of its medication breadth (Wegovy pen, Wegovy pill, Zepbound, Foundayo, Ozempic) and insurance concierge. Walgreens wins for no-subscription self-pay; GoodRx Care wins for low-fee pharmacy pickup. If branded coverage isn't accessible, the PlexusDx compounded cash-pay path starts at $129/mo on the Microdose GLP-1 Protocol.

Which brand-name provider is cheapest without insurance?

For oral starting doses, Ro and GoodRx Care both come in at $188 month one ($39 platform + $149 medication). Walgreens is $198 with no recurring fee. Year over year, the cheapest cash-pay path overall is the PlexusDx Microdose GLP-1 Protocol at $129/mo flat ($1,548/year all-inclusive) — which dispenses compounded GLP-1, not the branded drug.

Which provider has no monthly subscription?

Walgreens Weight Management. Pay $49 per visit, no recurring membership. PlexusDx is also no-membership — the monthly protocol price is the only charge, and you can pause or cancel at any time.

Can I get Wegovy, Zepbound, or Foundayo through PlexusDx?

No. PlexusDx dispenses compounded semaglutide and compounded tirzepatide through licensed U.S. compounding pharmacies, not the FDA-approved branded finished products. If your priority is specifically the branded medication, Ro, Walgreens, GoodRx Care, Hims & Hers, Sesame, or WeightWatchers are the right starting points.

Are compounded GLP-1 medications FDA-approved?

No. Compounded semaglutide and compounded tirzepatide are pharmacy-prepared formulations of the same active ingredients found in Wegovy, Ozempic, Zepbound, and Mounjaro, but the compounded products themselves are not FDA-approved finished drugs. They are dispensed under U.S. compounding regulations by licensed pharmacies. PlexusDx never describes its protocols as FDA-approved.

What happens if my insurance denies coverage for a branded GLP-1?

You generally have four options: appeal through the prescribing provider (Ro and PlushCare offer structured appeal support), use a manufacturer direct-to-consumer program (Lilly Direct Zepbound at $499/mo, Novo Direct Wegovy at intro pricing), pay cash retail through Walgreens or GoodRx, or pivot to a compounded cash-pay protocol like PlexusDx Semaglutide Injection ($149/mo) or Tirzepatide Injection ($249/mo).

Does PlexusDx require a membership or insurance?

No. PlexusDx is cash-pay, no membership, available in all 50 states (five require a live consult instead of async intake). Each monthly protocol price includes the provider consultation, prescription, compounded medication, and shipping in one bill.

Best Brand-Name GLP-1 Telehealth Providers (2026): Where PlexusDx Fits as the Compounded Cash-Pay Alternative | PlexusDx